Patents by Inventor Shenghua Shi

Shenghua Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PPAR active compounds
    Publication number: 20080234349
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Application
    Filed: September 6, 2006
    Publication date: September 25, 2008
    Inventors: Jack Lin, Shenghua Shi, Chao Zhang, Rebecca Zuckerman, Dean R. Artis, Prabha N. Ibrahim, Byunghun Lee
  • PPAR ACTIVE COMPOUNDS
    Publication number: 20080221127
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Application
    Filed: March 5, 2008
    Publication date: September 11, 2008
    Inventors: Jack Lin, Patrick Womack, Shenghua Shi, Chao Zhang, Dean R. Artis, Prabha N. Ibrahim, Weiru Wang
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20080188514
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 7, 2008
    Inventors: Guoxian Wu, Wayne Spevak, Songyuan Shi, Hanna Cho, Prabha N. Ibrahim, Chao Zhang, Shenghua Shi, Yong Zhou, Dean Artis, Jiazhong Zhang
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20080167338
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 10, 2008
    Inventors: Wayne Spevak, Hanna Cho, Prabha N. Ibrahim, Shenghua Shi, Shumeye Mamo, Samuel J. Gillette, Hongyao Zhu
  • PPAR active compounds
    Publication number: 20070072904
    Abstract: Compounds are described that are active on PPARs, including pan-active compounds and compounds selective for any one or any two of PPAR?, PPAR? and PPAR?. Also described are methods of use of the compounds in treating various diseases.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 29, 2007
    Inventors: Jack Lin, Patrick Womack, Byunghun Lee, Shenghua Shi, Chao Zhang, Rebecca Zuckerman, Dean Artis, Prabha Ibrahim, Weiru Wang
  • PPAR active compounds
    Publication number: 20060135540
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Application
    Filed: November 29, 2005
    Publication date: June 22, 2006
    Inventors: Jack Lin, Prabha Ibrahim, Dean Artis, Chao Zhang, Weiru Wang, Shenghua Shi
  • PPAR active compounds
    Publication number: 20060116416
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Application
    Filed: November 29, 2005
    Publication date: June 1, 2006
    Inventors: Jack Lin, Dean Artis, Prabha Ibrahim, Chao Zhang, Rebecca Zuckerman, Ryan Bremer, Shenghua Shi, Byunghun Lee
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi
  • Glucagon antagonists/inverse agonists
    Patent number: 6875760
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 5, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jøgensen, Janos Tibor Kodra, Shenghua Shi
  • Glucagon antagonists/inverse agonists
    Publication number: 20030220350
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: August 30, 2002
    Publication date: November 27, 2003
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
  • Glucagon antagonists/inverse agonists
    Patent number: 6613942
    Abstract: Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: September 2, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Ling, Vlad Gregor, Javier Gonzalez, Yufeng Hong, Dan Kiel, Atsuo Kuki, Shenghua Shi, Lars Naerum, Peter Madsen, Christian Sams, Jesper Lau, Michael Bruno Plewe, Jun Feng, Min Teng, Michael David Johnson, Kimberly Ann Teston, Ulla Grove Sidelmann, Lotte Bjerre Knudsen
  • Glucagon antagonists/inverse agonists
    Patent number: 6503949
    Abstract: Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: January 7, 2003
    Assignee: Noro Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Shenghua Shi